Which laboratory result is crucial for the nurse to report to the health care provider in a client with hypertension on candesartan?

Hyperkalemia is a critical laboratory finding that needs prompt communication to the healthcare provider for a client on candesartan, which is an angiotensin II receptor blocker (ARB). These medications can lead to increased potassium levels because they affect the renal system's regulation of electrolytes.

In a client with hypertension who is on candesartan, hyperkalemia could pose significant risks, including dangerous cardiac arrhythmias. Monitoring potassium levels is essential for patients on ARBs, as they may cause the body to retain potassium, especially if combined with other medications such as diuretics or in cases of renal impairment. Therefore, reporting hyperkalemia is crucial to ensure timely interventions and adjustments to the treatment plan to prevent potential complications.

The relevance of the other findings, while potentially significant in their own contexts, does not carry the same immediate urgency in relation to candesartan therapy.